Search

Your search keyword '"Jalees, Farhan"' showing total 4 results
Start Over Author "Jalees, Farhan"
4 results on '"Jalees, Farhan"'

1. Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes

Author

Zafar Rasheed, A Al Salloom, Uzma Zafar, Hani A. Al-Shobaili, Jalees Farhan, and A R Meki

Subjects
Microbiology (medical), Adult, Male, endocrine system, endocrine system diseases, Adolescent, Clinical Biochemistry, Immunology, Interleukin-1beta, Vitiligo, Inflammation, medicine.disease_cause, Microbiology, Autoimmunity, Pathogenesis, Young Adult, immune system diseases, Diabetes mellitus, Immunology and Allergy, Medicine, Humans, Interleukin 6, Child, Type 1 diabetes, biology, business.industry, Interleukin-6, Tumor Necrosis Factor-alpha, Biochemistry (medical), nutritional and metabolic diseases, Interleukin, Middle Aged, medicine.disease, Peptide Fragments, Infectious Diseases, Diabetes Mellitus, Type 1, biology.protein, Female, medicine.symptom, Inflammation Mediators, business, Biomarkers
Abstract

Vitiligo is a pigmentation disorder of unknown aetiology, but it has been reported in association with other autoimmune diseases including type 1 diabetes mellitus (T1D). Vitiligo and T1D share a common theory of autoimmunity, but still an inflammatory link between them remains to be investigated. This study investigates the status and contribution of the inflammatory markers tumour necrosis factor-α (TNFα), interleukin (IL)-6 and IL-1 in patients with vitiligo, T1D and vitiligo-associated T1D (Vt-T1D). The data showed that sera from Vt-T1D patients (n = 21) had higher levels of TNFα, IL-6 and IL-1β compared with vitiligo patients (n = 39), T1D patients (n = 37) or controls (n = 42). Interestingly, serum levels of IL-6 were found to be significantly higher in Vt-T1D patients compared with the levels of TNFα and IL-1β. These data also showed that IL-6 was high in Vt patients as compared to the levels of TNFa and L-1β, whereas in T1D patients, IL-6 and TNFα were almost the same but were higher than IL-1β. In conclusion, this is the first study to show an inflammatory link between vitiligo and T1D. The data conclude that IL-6 plays an important role in the pathogenesis of Vt-T1D patients and is likely to gain favour as a therapeutic target in these patients.

Published
2015

4. Efficacy of a classical antiobesity Unani pharmacopial formulation (Safoof-e-Muhazzil) in systolic and diastolic blood pressure: A randomized, open-labeled, controlled clinical study.

Author

Khan, Asim Ali, Jahangir, Umar, Jalees, Farhan, Kapoor, Prem, and Urooj, Shaista

Subjects
ANTIOBESITY agents, ARAB medicine, BLOOD pressure, RANDOMIZED controlled trials, DRUG efficacy, HYPERTENSION
Abstract

The aim of this study is to evaluate the efficacy of a Unani formulation in hypertension. A total of 90 patients with total cholesterol level of more than 220 mg/dl with associated conditions were included in this study. A total of 30 patients having a mean systolic blood pressure (BP) of 133.86 mmHg comprising Group A received Unani formulation Safoof-e-Muhazzil (SM) in its classical powder form in the dose of 5 g twice a day orally. Group B comprising of 30 patients with a mean systolic BP of 133.13 mmHg received same drug, but in compressed tablet form in the same dosage, whereas, 30 patients comprising Group C with a mean systolic BP of 129.45 mmHg, received Atorvastatin 10 mg as a standard control. Patients were evaluated on each follow-up at 2nd, 4th and 6th week. The mean systolic BP in Group A and B before treatment was 133.86 ± 3.028 mmHg and 133.13 ± 2.852 mmHg, which significantly decreased to 119.33 ± 1.922 mmHg (P < 0.001) and 119 ± 1.760 mmHg (P < 0.001) respectively. In the control Group C before treatment BP was 129.45 ± 2.499 mmHg and after treatment it significantly decreased to 124.34 ± 1.794 mmHg (P < 0.01). The percentage change after treatment was 10.85%, 10.61% and 3.94% respectively in each group. Mean diastolic BP in Group A and B before treatment was 85.06 ± 2.11 mmHg and 84.56 ± 1.5 mmHg, which significantly decreased to 79.06 ± 1.56 mmHg (P < 0.001) and 79.96 ± 1.15 mmHg (P < 0.001) respectively, BP before treatment in Group C was 83.23 ± 1.588 mmHg, which was decreased to 124.34 ± 1.794 mmHg (P < 0.01). The study results indicate that the test drug was quite effective in reducing both systolic as well as diastolic BP. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results